SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase 3 clinical trials for the treatment of desmoid tumors. The company is also developing mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas; Nirogacestat + belantamab mafodotin -blmf, which is in Phase Ib clinical trial for the treatment of relapsed or refractory multiple myeloma (RRMM); and Nirogacestat + ALLO-715 that is in Phase 1 clinical trial for the treatment of RRMM. In addition, it is developing Nirogacestat + teclistamab, which is in clinical stage that targets BCMA and CD3; Nirogacestat + elranatamab; Nirogacestat + PBCAR269A, which is in Phase 1/2a clinical trial for allogeneic BCMA CAR T cell therapy; Mirdametinib that is in Phase 1/2a clinical trial for the treatment of NF1-PN; Mirdametinib + lifirafenib, a combination therapy that is in Phase 1b/2 clinical trial in patients with advanced or refractory solid tumors; and BGB-3245, an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations, which is in Phase I clinical trial. The company has collaborations with BeiGene, Ltd., GlaxoSmithKline LLC, and Allogene to develop combination approaches with nirogacestat and mirdametinib; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology; and clinical trial collaboration agreement with Seagen Inc. SpringWorks Therapeutics, Inc. was founded in 2017 and is headquartered in Stamford, Connecticut.
IPO Year: 2019
Exchange: NASDAQ
Website: springworkstx.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/20/2024 | $60.00 | Outperform | Evercore ISI |
| 2/5/2024 | $75.00 | Buy | Guggenheim |
| 12/1/2022 | $45.00 | Buy | BofA Securities |
| 9/8/2021 | $97.00 → $105.00 | Overweight | JP Morgan |
| 8/5/2021 | $136.00 → $137.00 | Buy | HC Wainwright & Co. |
4 - SpringWorks Therapeutics, Inc. (0001773427) (Issuer)
4 - SpringWorks Therapeutics, Inc. (0001773427) (Issuer)
4 - SpringWorks Therapeutics, Inc. (0001773427) (Issuer)
4 - SpringWorks Therapeutics, Inc. (0001773427) (Issuer)
4 - SpringWorks Therapeutics, Inc. (0001773427) (Issuer)
4 - SpringWorks Therapeutics, Inc. (0001773427) (Issuer)
4 - SpringWorks Therapeutics, Inc. (0001773427) (Issuer)
4 - SpringWorks Therapeutics, Inc. (0001773427) (Issuer)
4 - SpringWorks Therapeutics, Inc. (0001773427) (Issuer)
4 - SpringWorks Therapeutics, Inc. (0001773427) (Issuer)
DEFM14A - SpringWorks Therapeutics, Inc. (0001773427) (Filer)
PREM14A - SpringWorks Therapeutics, Inc. (0001773427) (Filer)
8-K - SpringWorks Therapeutics, Inc. (0001773427) (Filer)
10-Q - SpringWorks Therapeutics, Inc. (0001773427) (Filer)
SCHEDULE 13G/A - SpringWorks Therapeutics, Inc. (0001773427) (Subject)
DEFA14A - SpringWorks Therapeutics, Inc. (0001773427) (Filer)
DEFA14A - SpringWorks Therapeutics, Inc. (0001773427) (Filer)
8-K - SpringWorks Therapeutics, Inc. (0001773427) (Filer)
DEFA14A - SpringWorks Therapeutics, Inc. (0001773427) (Filer)
DEF 14A - SpringWorks Therapeutics, Inc. (0001773427) (Filer)
For Immediate Release: November 27, 2023 Today, the U.S. Food and Drug Administration approved Ogsiveo (nirogacestat) tablets for adult patients with progressing desmoid tumors who require systemic treatment. Ogsiveo is the first drug to be approved for the treatment of patients with desmoid tumors, a rare subtype of soft tissue sarcomas. Desmoid tumors are non-cancerous but can be locally aggressive. The tumor
Submission status for SPRINGWORKS THERAPEUTICS INC's drug OGSIVEO (ORIG-1) with active ingredient NIROGACESTAT has changed to 'Approval' on 11/27/2023. Application Category: NDA, Application Number: 217677, Application Classification: Type 1 - New Molecular Entity
– If approved, mirdametinib is expected to be the first and only therapy in the European Union with marketing authorization for both adults and children with NF1-PN – – Decision from European Commission expected in the third quarter of 2025 – STAMFORD, Conn., May 23, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (NASDAQ:SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a conditional marketing authorization for mirdametinib, a MEK inhibitor, for the treatment of s
– Purchase price of $47 per share in cash represents an equity value of approximately $3.9 billion, or an enterprise value of $3.4 billion (€3.0 billion) – – Planned acquisition will immediately add revenue and accelerate mid- to long-term growth for Merck KGaA, Darmstadt, Germany's Healthcare business – – SpringWorks Therapeutics is a U.S. biopharmaceutical company with a first-in-class, systemic standard-of-care therapy in adults with desmoid tumors and the first and only approved therapy for adults and children with neurofibromatosis type 1-associated plexiform neurofibromas – – Planned acquisition will strengthen the presence of Merck KGaA, Darmstadt, Germany's Healthcare business in
Purchase price of $47 per share in cash represents an enterprise value of €3.0 billion ($3.4 billion), or an equity value of approximately $3.9 billion Planned acquisition will immediately add revenue and accelerate mid- to long-term growth for the Healthcare business of Merck KGaA, Darmstadt, Germany SpringWorks Therapeutics is a U.S. biopharmaceutical company with a first-in-class, systemic standard-of-care therapy in adults with desmoid tumors and the first and only approved therapy for adults and children with neurofibromatosis type 1-associated plexiform neurofibromas Planned acquisition will strengthen the presence of the Healthcare business of Merck KGaA, Darmstadt, Germany, i
STAMFORD, Conn., April 27, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (NASDAQ:SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced today that the Company anticipates the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) will adopt an opinion on the marketing authorization application (MAA) for nirogacestat, an oral gamma secretase inhibitor, for the treatment of adults with desmoid tumors in the second quarter of 2025. About SpringWorks Therapeutics SpringWorks is a commercial-stage biopharmaceutical company dedicated to improving the lives of patients with severe rare diseases an
– Achieved $61.5 million and $172.0 million in fourth quarter and full year 2024 OGSIVEO® (nirogacestat) U.S. net product revenues, respectively – – Received FDA approval of GOMEKLI™ (mirdametinib) for the treatment of adult and pediatric patients with symptomatic NF1-PN not amendable to complete resection – – Ended 2024 with $461.9 million in cash, cash equivalents and marketable securities – STAMFORD, Conn., Feb. 20, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (NASDAQ:SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today reported financial results for the fourth quarter and full year periods ended December 31, 2024 and provi
- Educational campaign aims to raise awareness and drive conversation about desmoid tumors, the devastating impact they have on patients' lives - STAMFORD, Conn., Feb. 19, 2025 /PRNewswire/ -- SpringWorks Therapeutics, Inc. (NASDAQ:SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, and Jennifer Fisher, jewelry designer and desmoid tumor patient advocate, are collaborating to increase understanding of desmoid tumors as well as to encourage patients to find a specialist, like an oncologist with experience treating desmoid tumors who can discuss available treatment options to manage their desmoid tumor. Desmoid tumors ar
– GOMEKLI is the first and only medicine approved for both adults and children with NF1-PN – – Approval based on positive data from Phase 2b ReNeu trial, which showed GOMEKLI treatment resulted in robust ORR, deep and durable reductions in tumor volume, and a manageable safety profile – – SpringWorks granted rare pediatric disease priority review voucher by the FDA – Photos accompanying this announcement are available at: https://www.globenewswire.com/NewsRoom/AttachmentNg/8eb8effc-49a5-4b24-911f-d3e6dfa9c8a9https://www.globenewswire.com/NewsRoom/AttachmentNg/f1041678-3f79-43b7-a101-2390fb8cb86bhttps://www.globenewswire.com/NewsRoom/AttachmentNg/7d8cb318-e5f8-4944-8736-24cb19a5dec9https
– GOMEKLI is the first and only medicine approved for both adults and children with NF1-PN – – Approval based on positive data from Phase 2b ReNeu trial, which showed GOMEKLI treatment resulted in robust ORR, deep and durable reductions in tumor volume, and a manageable safety profile – – SpringWorks granted rare pediatric disease priority review voucher by the FDA – Photos accompanying this announcement are available at: https://www.globenewswire.com/NewsRoom/AttachmentNg/8eb8effc-49a5-4b24-911f-d3e6dfa9c8a9https://www.globenewswire.com/NewsRoom/AttachmentNg/f1041678-3f79-43b7-a101-2390fb8cb86bhttps://www.globenewswire.com/NewsRoom/AttachmentNg/7d8cb318-e5f8-4
STAMFORD, Conn., Jan. 30, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (NASDAQ:SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Thursday, February 20, 2025 to report its fourth quarter and full year financial results and discuss recent business updates. To join the live webcast and view the corresponding slides, please click here. To participate in the live conference call by phone, please click here to pre-register. Registered participants will then be provided with a dial-in number and conference code to access the call. A replay of the webcas
– Achieved $61.5 million and $172.0 million in preliminary fourth quarter and full year 2024 OGSIVEO® (nirogacestat) U.S. net product revenues, respectively – – Ended 2024 with approximately $462 million in cash, cash equivalents, and marketable securities – – Additional updates across Company's commercial portfolio and investigational pipeline to be provided during J.P. Morgan Healthcare conference presentation today at 11:15 a.m. PT – STAMFORD, Conn., Jan. 13, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (NASDAQ:SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced its preliminary fourth quarter and full year 2024 U.
– Achieved $61.5 million and $172.0 million in fourth quarter and full year 2024 OGSIVEO® (nirogacestat) U.S. net product revenues, respectively – – Received FDA approval of GOMEKLI™ (mirdametinib) for the treatment of adult and pediatric patients with symptomatic NF1-PN not amendable to complete resection – – Ended 2024 with $461.9 million in cash, cash equivalents and marketable securities – STAMFORD, Conn., Feb. 20, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (NASDAQ:SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today reported financial results for the fourth quarter and full year periods ended December 31, 2024 and provi
STAMFORD, Conn., Jan. 30, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (NASDAQ:SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Thursday, February 20, 2025 to report its fourth quarter and full year financial results and discuss recent business updates. To join the live webcast and view the corresponding slides, please click here. To participate in the live conference call by phone, please click here to pre-register. Registered participants will then be provided with a dial-in number and conference code to access the call. A replay of the webcas
– Achieved $49.3 million in OGSIVEO® (nirogacestat) net product revenue in the third quarter – – Long-term follow-up data from the Phase 3 DeFi trial of nirogacestat in adults with desmoid tumors highlight further reductions in tumor size, increase in ORR, sustained improvement in desmoid tumor symptoms, and consistent safety profile – – Granted FDA Priority Review on NDA and received validation of EU Marketing Authorization Application for mirdametinib for the treatment of adults and children with NF1-PN – – $498 million in cash, cash equivalents and marketable securities as of September 30, 2024; expected to fund the Company through profitability, which is anticipated in the first
STAMFORD, Conn., Oct. 22, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (NASDAQ:SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Tuesday, November 12, 2024 to report its third quarter financial results and discuss recent business updates. To join the live webcast and view the corresponding slides, please click here. To participate in the live conference call by phone, please click here to pre-register. Registered participants will then be provided with a dial-in number and conference code to access the call. A replay of the webcast will be availa
– Achieved $40.2 million in OGSIVEO® (nirogacestat) net product revenue in the second quarter – – Completed submission of NDA to the FDA for mirdametinib for the treatment of children and adults with NF1-PN – – Presented Phase 2b ReNeu trial results and additional analyses from Phase 3 DeFi trial at the 2024 ASCO Annual Meeting – – Initiated Phase 1a trial of SW-682 in patients with Hippo mutant solid tumors – STAMFORD, Conn., Aug. 07, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (NASDAQ:SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today reported financial results for the second quarter of 2024 and provided an update
STAMFORD, Conn., July 23, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (NASDAQ:SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Wednesday, August 7, 2024 to report its second quarter financial results and discuss recent business updates. To join the live webcast and view the corresponding slides, please click here. To participate in the live conference call by phone, please click here to pre-register. Registered participants will then be provided with a dial-in number and conference code to access the call. A replay of the webcast will be availa
– Achieved $21.0 million in OGSIVEO® (nirogacestat) net product revenue in the first quarter – – Received validation from the EMA for MAA of nirogacestat for the treatment of adults with desmoid tumors – – Initiated rolling submission of NDA to the FDA for mirdametinib for the treatment of children and adults with NF1-PN – – Phase 2b ReNeu trial results accepted for oral presentation at the 2024 ASCO Annual Meeting – STAMFORD, Conn., May 02, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (NASDAQ:SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today reported first quarter financial results for the period ended March 31, 2024 and
STAMFORD, Conn., April 18, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (NASDAQ:SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced that it will host a live conference call and webcast at 8:30 a.m. E.T. on Thursday, May 2, 2024 to report its first quarter financial results and discuss recent business updates. To join the live webcast and view the corresponding slides, please click here. To access the live call by phone, please pre-register for the call by clicking here. Once registration is complete, participants will be provided with a dial-in number and conference code to access the call. A replay of the webcast will
– Approval based on positive data from Phase 3 DeFi trial, in which OGSIVEO significantly improved progression-free survival and objective response rate, with rapid and sustained improvements in pain, physical functioning and overall quality of life – – SpringWorks to host conference call tomorrow at 8:00 a.m. ET – A Media Snippet accompanying this announcement is available by clicking on this link. STAMFORD, Conn., Nov. 27, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (NASDAQ:SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced today that the U.S. Food and Drug Administration (FDA) has approved OGSIVEO™ (nirogacestat), a
– Confirmed objective response rate of 52% in pediatric patients and 41% in adult patients, as assessed by Blinded Independent Central Review – – Mirdametinib treatment resulted in deep and durable responses and significant improvements in key secondary patient-reported outcome measures – – Mirdametinib was generally well tolerated with low rates of Grade 3+ adverse events – – Additional data expected to be presented at medical conference and NDA submission to the U.S. FDA planned in the first half of 2024 – – Company to host conference call today at 8:30 a.m. Eastern Time – STAMFORD, Conn., Nov. 16, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (NASDAQ:SWTX), a clinical-st
STAMFORD, Conn., July 29, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (NASDAQ:SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced the appointment of Martin Mackay, Ph.D. to the Company's Board of Directors. Dr. Mackay is a highly accomplished research and development (R&D) executive with more than 30 years of pharmaceutical and biotech R&D experience, including leadership roles at Pfizer, AstraZeneca and Alexion. "Martin is a proven industry leader whose experience in developing and delivering novel treatments to patients in need is exceptional," said Saqib Islam, Chief Executive Officer of SpringWorks. "His expertise
STAMFORD, Conn., Sept. 11, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (NASDAQ:SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced the appointment of Tai-An Lin, Ph.D., as its Chief Scientific Officer. Dr. Lin brings more than 25 years of biotechnology and global pharmaceutical experience in advancing drug discovery programs from target identification through early clinical trials across the therapeutic areas of oncology, immuno-oncology, and immunology. "Tai-An is a talented scientist with a strong track record of advancing innovative oncology programs from discovery
STAMFORD, Conn., July 15, 2022 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (NASDAQ:SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced the appointment of Carlos Albán to the Company's Board of Directors. Mr. Albán, who served as Vice Chairman and Chief Commercial Officer at AbbVie, Inc. ("AbbVie") until his retirement last year, brings over 30 years of experience in global commercial strategy and operations. "Carlos' success in building and leading global commercial organizations will be valuable as SpringWorks continues its planned transition into a commercial-stage compa
NEW YORK, Nov. 11, 2021 /PRNewswire/ -- Gilgamesh Pharmaceuticals, a mental health focused biotechnology company developing novel psychedelic-related medicines for the treatment of neuropsychiatric conditions, today announced the addition of several key additions to its leadership team and board of directors. The additions will enable Gilgamesh to rapidly advance its pipeline toward clinical trials beginning in late 2022 and further expand its IP portfolio. Key hires include: Chief Medical Officer Gerard Marek, MD/Ph.D. is a renowned expert on serotonin system biology. Gerard is a former asst. professor at Yale University and was the Chief Scientific Officer of Psychiatric Disorders Discove
STAMFORD, Conn., May 10, 2021 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (NASDAQ:SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, announced today that Mike Burgess, M.B.Ch.B., Ph.D. has been appointed Head of Research and Development (R&D). Dr. Burgess is a physician-scientist with clinical experience in pediatrics and pediatric oncology and over 20 years of pharmaceutical industry R&D leadership experience across several therapeutic areas, including oncology. Dr. Burgess will lead the R&D organization as the company continues to advance its diversified targeted oncology pipeline and t
Evercore ISI initiated coverage of SpringWorks Therapeutics with a rating of Outperform and set a new price target of $60.00
Guggenheim initiated coverage of SpringWorks Therapeutics with a rating of Buy and set a new price target of $75.00
BofA Securities initiated coverage of SpringWorks Therapeutics with a rating of Buy and set a new price target of $45.00
JP Morgan reiterated coverage of SpringWorks Therapeutics with a rating of Overweight and set a new price target of $105.00 from $97.00 previously
HC Wainwright & Co. reiterated coverage of SpringWorks Therapeutics with a rating of Buy and set a new price target of $137.00 from $136.00 previously
Goldman Sachs resumed coverage of SpringWorks Therapeutics with a rating of Buy and set a new price target of $112.00
HC Wainwright reiterated coverage of SpringWorks Therapeutics with a rating of Buy and set a new price target of $124.00 from $101.00 previously
Barclays reiterated coverage of SpringWorks Therapeutics with a rating of Overweight and set a new price target of $105.00 from $92.00 previously
HC Wainwright & Co. reiterated coverage of SpringWorks Therapeutics with a rating of Buy and set a new price target of $124.00 from $101.00 previously
Barclays reiterated coverage of SpringWorks Therapeutics with a rating of Overweight and set a new price target of $92 from $83 previously
SC 13G/A - SpringWorks Therapeutics, Inc. (0001773427) (Subject)
SC 13G/A - SpringWorks Therapeutics, Inc. (0001773427) (Subject)
SC 13G/A - SpringWorks Therapeutics, Inc. (0001773427) (Subject)
SC 13G/A - SpringWorks Therapeutics, Inc. (0001773427) (Subject)
SC 13G/A - SpringWorks Therapeutics, Inc. (0001773427) (Subject)
SC 13G/A - SpringWorks Therapeutics, Inc. (0001773427) (Subject)
SC 13G/A - SpringWorks Therapeutics, Inc. (0001773427) (Subject)
SC 13D/A - SpringWorks Therapeutics, Inc. (0001773427) (Subject)
SC 13D/A - SpringWorks Therapeutics, Inc. (0001773427) (Subject)
SC 13G - SpringWorks Therapeutics, Inc. (0001773427) (Subject)